Medical Condition News

RSS

More findings on genetic complexity behind type 2 diabetes

Using a new method, diabetes researchers at Lund University, Sweden, have been able to reveal more of the genetic complexity behind type 2 diabetes.

5 Sep 2012

Study evaluates prognostic utility of novel biomarkers of cardiovascular stress

Critical Diagnostics announced today, Circulation, an American Heart Association Journal, released online the first study evaluating the power of ST2 to predict development of heart failure and other adverse outcomes in the general population titled, "Prognostic Utility of Novel Biomarkers of Cardiovascular Stress: The Framingham Heart Study".

5 Sep 2012

Sleep apnoea severity associated with increased cancer mortality

Sleep apnoea severity has been associated with increased cancer mortality in a new study.

5 Sep 2012

Smoker's pack-years, age and area of emphysema are strong predictors of mortality in COPD

Identifying an individual's the smoking history could help doctors to predict survival time in people with COPD.

5 Sep 2012

Exposure to volcanic ash increases respiratory symptoms

Exposure to volcanic ash can increase respiratory symptoms such as an extreme cough, or phlegm, according to a new study.

5 Sep 2012

First global benchmarks for assessing lung function across entire life span

New research has established the first global benchmarks for assessing lung function across the entire life span. The lung growth charts will help healthcare professionals better understand lung disease progression and help raise awareness of lung disease, which is the world's leading cause of death.

5 Sep 2012

NCI awards Soligenix $300,000 SBIR grant for orBec Phase 2 chronic GI GVHD trial

Soligenix, Inc., a development stage biopharmaceutical company, announced today that the National Cancer Institute has awarded Soligenix a Small Business Innovation Research grant to support the conduct of a Phase 2 clinical trial designed to evaluate orBec (oral beclomethasone 17,21-dipropionate or BDP) as a treatment for the gastrointestinal manifestation of chronic Graft-versus-Host disease.

5 Sep 2012

Zalicus commences first of two Z160 Phase 2a clinical studies for chronic neuropathic pain

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced that it has initiated the first of two Phase 2a clinical studies with Z160, its first-in-class, oral, state-dependent, selective N-type calcium channel blocker for the treatment of chronic neuropathic pain indications.

5 Sep 2012

Phase 1b trial validates efficacy of Pulmatrix PUR118 to treat COPD

Pulmatrix, Inc., a clinical stage biotechnology company creating novel inhaled therapeutics, today announced top line results from a clinical study showing that the novel inhaled therapeutic, PUR118, demonstrated anti-inflammatory efficacy and was well-tolerated in two Phase 1b studies in patients with chronic obstructive pulmonary disease (COPD).

5 Sep 2012

Strong antiviral antibody response observed in oral administration of Flucide

NanoViricides, Inc. announced today that anti-influenza drug candidates under its FluCide program, when given orally, led to strong antiviral antibody response. The antibody response with Oral administration was stronger than that with IV administration and was substantially greater than that observed with oseltamivir.

5 Sep 2012

ARGO Medical, Cyclone Technologies announce availability of ReWalk exoskeleton system

Exoskeleton technology leader, ARGO Medical Technologies, along with mobility solutions provider, Cyclone Technologies, announced today that Claire Lomas has become the first person to take home an exoskeleton system for personal use.

5 Sep 2012

New strategy for outsmarting cancer through its own social intelligence

In the face of mounting evidence that cancer cells communicate, cooperate and even engage in collective decision-making, biophysicists and cancer researchers at Rice University, Tel Aviv University and Johns Hopkins University are suggesting a new strategy for outsmarting cancer through its own social intelligence.

5 Sep 2012

Chemical properties of green tea benefit memory and spatial learning

It has long been believed that drinking green tea is good for the memory. Now researchers have discovered how the chemical properties of China's favorite drink affect the generation of brain cells, providing benefits for memory and spatial learning. The research is published in Molecular Nutrition & Food Research.

5 Sep 2012

Baxter seeks FDA BLA approval for BAX 326 rFIX protein to treat hemophilia B

Baxter International Inc. today announced that the company has submitted a biologics license application to the United States Food and Drug Administration for approval of BAX 326, a recombinant factor IX (rFIX) protein being investigated for the treatment and prophylaxis of bleeding episodes for patients over 12 years of age with hemophilia B.

From Baxter International Inc. 5 Sep 2012

Roadmap to areas of the brain associated with affective aggression

A North Carolina State University researcher has created a roadmap to areas of the brain associated with affective aggression in mice. This roadmap may be the first step toward finding therapies for humans suffering from affective aggression disorders that lead to impulsive violent acts.

5 Sep 2012

Regular Fanconi anemia cells aren't sensitive to resveratrol

Fanconi anemia is a recessive genetic disorder affecting 1 in 350,000 babies, which leaves cells unable to repair damaged DNA. This lack of repair puts Fanconi anemia patients at high risk for developing a variety of cancers, especially leukemias and head and neck cancer.

5 Sep 2012

FDA approves Bosulif to treat chronic myelogenous leukemia

The U.S. Food and Drug Administration today approved Bosulif (bosutinib) to treat chronic myelogenous leukemia (CML), a blood and bone marrow disease that usually affects older adults.

5 Sep 2012

Scientists identify master regulator essential for progression and relapse of deadly brain cancer

A*STAR scientists have identified a biomarker of the most lethal form of brain tumours in adults- glioblastoma multiforme. The scientists found that by targeting this biomarker and depleting it with a potential drug, they were able to prevent the progression and relapse of the brain tumour.

5 Sep 2012

ImmusanT commences Nexvax2 clinical trials for celiac disease in New Zealand, Australia and the U.S.

ImmusanT announced today that it has initiated clinical trials in New Zealand, Australia and the U.S. to evaluate Nexvax2, the first therapeutic vaccine for patients with celiac disease. Nexvax2 is designed to re-establish patients' tolerance to the toxic effects of gluten, a protein in wheat, barley and rye, and allow them to return to a normal diet.

5 Sep 2012

AlloCure commences AC607 Phase 2 clinical trial for acute kidney injury

AlloCure, Inc. today announced that it has initiated a phase 2 clinical trial of AC607, the company's mesenchymal stem cell therapy, as a potential treatment for acute kidney injury.

5 Sep 2012